At the completion of the clinical evaluation, based on the information received, the clinical evaluation refuted the reported type 2 endoleak.However, a type 3a endoleak with complete component separation was confirmed through patient imaging.No procedure related issue, user related issue, anatomy related issue, or contributing cautionary including off-label product use conditions could be determined due to lack of information surrounding the event.The remodeling of the system as the devices separated likely caused a stent graft collapse of the main body.Currently, there have been no reports of further negative patient sequelae; there has been no evidence of a repair procedure.The event devices remain implanted in the patient and were not available for further evaluation.The review of the manufacturing lot confirmed all devices met specifications prior to release.A root cause investigation was carried out for all afx complaints having an identified failure mode of a type 3a endoleak.The root causes have been identified as; patient anatomy including large aneurysms, aneurysm sac angulation, significant aortic neck angulation and lack of thrombus; patient conditions including disease progression or anatomical changes post implant; off label product use including patient anatomy, overlap length, oversizing between components, and placement of the devices within the anatomy of the patient.Endologix implemented the following corrective actions to reduce the type 3a endoleak events; sizing guidance and instructions were updated in the ifu and released on 06/17/2015, field training was completed by 08/03/2015.Since the corrective actions were implemented the type 3a events have been reduced significantly and are well within the acceptable range per our risk assessment.No additional investigations of this reported complaint are planned, endologix will continue to monitor this complaint and similar complaints in the event further investigation is needed.
|